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Abstract
Background: The prevalence, genotypes, and vertical transmission characteristics of human papillomavirus (HPV)
among pregnant women from Nanjing, China was investigated.
Methods: Cervical cells were collected from healthy pregnant women (n = 3139; stage of gestation, 24.6 ±
2.1 weeks) for cytological evaluation and determination of HPV infection status. Exfoliated oral and genital cells
were collected from neonates (<1-day-old, n = 233) whose mothers were positive for HPV DNA. We used HPV Gene
Chip technology with 23 HPV genotype probes to conduct our analysis.
Results: Overall prevalence of HPV DNA among pregnant women was 13.4% (422/3139). The most frequently
detected HPV genotypes were HPV-16 (29.6%, 125/422), -18 (14.7%, 62/422), and -58 (14.2%, 60/422). The rate of
concordance for HPV DNA in maternal-neonatal pairs was 23.6% (55/233), with HPV type-specific concordance
occurring in 26 cases. A higher prevalence of HPV DNA was apparent in female neonates compared with males
(17.7 vs. 11.6%).
Conclusions: The prevalence of cervical HPV DNA in pregnant women from Nanjing was low, with vertical
transmission rates slightly higher. From our findings, we concluded that there was efficient vertical transmission of
three HPV genotypes, with HPV-16 the most prevalent type in pregnant women and newborn babies.
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Background
Globally, cervical cancer is the second-most commonly
occurring cancer in women. In recent years, the occur-
rence of sexually transmitted infections (STIs) involving
human papillomavirus (HPV) has been increasing in
China, and are now second only to the incidence of STIs
for gonorrhea [1]. HPV has been recognized as the pri-
mary cause of cervical cancer, papillomatosis, and ano-
genital warts [2,3]. Low-risk, non-oncogenic forms of
HPV are associated with anogenital warts and laryngeal
papillomatosis; high-risk, oncogenic types are associated
with cancers of the cervix, anogenital areas, head and
neck [4].
In the early 1950s, a study revealed that pregnant
women infected with HPV were able to vertically trans-
mit the virus to neonates, resulting in infantile anal and
genital condyloma acuminatum, congenital conjunctival
papilloma, and juvenile laryngeal papillomatosis [5,6]. A
recent report involving 88 cases where the sexual life
history of females was followed indicated that congenital
infection of HPV might result in an increased risk of
genital condyloma acuminatum [7]. However, geographic
regions display different HPV genotype distribution
among ethnicities. The current methods of virus detec-
tion are based upon rates of congenital HPV infection,
which have been reported at 0–80.9% [8].
The five most prevalent HPV genotypes associated
with genital and oral cancers in females are HPV-16, -18, -
31, -58, and -52 [9]. Previous surveys in China have found
HPV-52 and -58 to be more prevalent than HPV-16 in
some areas [10,11]; this distribution is consistent with
those found in Japan and eastern Africa [9]. Most studies
have found a higher prevalence of HPV DNA among preg-
nant women compared with those who are not pregnant
[12-14].
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It was previously shown, using DNA hybridization
techniques, that HPV could not be detected in 11 oro-
pharyngeal samples taken from neonates (1-day-old).
However, from an age of 5 weeks up to 18 months, HPV
DNA could be detected [15]. This suggests that the virus
may be carried by the neonate even though it could not
be detected by DNA hybridization. Mant et al. [16]
reported using a more sensitive polymerase chain reac-
tion (PCR) detection method to detect HPV-16 DNA in
20 neonatal oropharyngeal samples. After 30 months,
eight samples were positive for virus.
Although there is overwhelming evidence for the sex-
ual transmission of high-risk HPV genotypes, several
studies have examined other routes, such as vertical
transmission before or during childbirth, direct contact
during labor, or horizontal transmission among children
through contact with infected skin lesions [17,18]. How-
ever, similar studies of transmission modes in different
regions have obtained disparate results. Studies of verti-
cal HPV transmission have reported a wide range of
neonatal infection rates. These conflicting findings are
primarily because of the differences in populations and
experimental techniques, and might have been influ-
enced by factors such as sex, type of delivery, and mater-
nal status before delivery.
It is important to examine the distribution of HPV
genotypes found in pregnant women, as it can guide the
development of genotype vaccines for the prevention of
cancer due to HPV infection [19]. The prevalence of ver-
tical HPV transmission may have an important impact
on clinical handling and vaccination strategies for
infected women during pregnancy. We sought to deter-
mine the prevalence, types, and vertical transmission




Healthy pregnant women (n = 3139) were recruited,
from a sample population of 11,696 women, who had
their first obstetric examinations at the Affiliated Drum
Tower Hospital (Nanjing University Medical School,
China) between January 2006 and April 2010. A follow-
up study was conducted after delivery. The exclusion
criteria for this study were: (1) near miscarriage or ab-
normal vaginal bleeding; (2) cervical lesions apparent
upon simple visual inspection during gynecological
examination; (3) sexual intercourse and/or vaginal medi-
cation in the previous 3 days; (4) HPV detected by cer-
vical cytological examination within 1 year; (5) mental or
physical incompetence; (6) in vitro fertilization (IVF);
and (7) refusal of gynecological examination. There were
1088 pregnant women that were excluded due to the ex-
clusion criteria. The mean age of the 3139 participants
was 29.9 years (range, 20–44 years). Most (81.5%, 2558/
3139) women were in the 22nd–26th week of gestation
upon enrollment in the study. All participating women
provided written informed consent.
Data collection
Sociodemographic information for all participants, from
January 2006 until April 2010, was obtained, along with
gestational age when samples were collected, and parity
data. A follow-up study was performed after delivery.
Samples were collected from all pregnant women and
from 233 infants of the 422 HPV-positive women due to
some mother refusing examination and sampling of the
infant. The sample collection was carefully executed to
prevent cross-contamination between subjects and ana-
tomical sites by using disposable equipment and chan-
ging the bed lining and collector’s gloves between each
subject. Sample collection was carefully performed to
prevent cross-contamination between subjects and ana-
tomical sites, by using disposable equipment, and chan-
ging bed linen and collector’s gloves before sampling
each subject. During gynecological examination, two cer-
vical smears were collected from each participant for
cervical cytological analysis and HPV detection. A cervix
brush was used to obtain exfoliated cells from the
squamocolumnar junction of the cervix. The collection
instrument was then rinsed in transport medium
[20,21]. A collection device (Decipher Bioscience, Shen-
zhen, China) was used to obtain cervical exfoliated cells
for HPV-DNA detection. In accordance with the
manufacturer’s instructions, samples were collected by
scraping the uterine cervical canal with a cervical brush
and sent to a diagnostic laboratory within 24 h. Less
than 24 h after birth, exfoliated oral and genital cells
were collected from the subset of clean neonates using
the same collection device used for HPV DNA detection.
Close contact of the child with the mother was avoided
to prevent contamination with the mother’s exfoliated
cells. Oral samples were obtained by allowing the neo-
nate to suck on the sampler for about 10 s. Genital
samples were collected from males by gently swabbing
the glans penis and the inner mucosal part of the pre-
puce. Specimens were obtained from females by gently
swabbing the vulvar mucosa. Tips containing cellular
material were then placed into transport medium tubes
and immediately stored at -20°C.
Laboratory methods
Cytological specimens were sent to a diagnostic path-
ology laboratory for examination, and prepared using a
ThinPrep 2000 Processor (AutoCyte Inc., Burlington,
NC, USA), according to the manufacturer’s instructions.
Cell suspensions were used to prepare liquid-based cy-
tology slides that were examined using the ThinPrep
Hong et al. BMC Infectious Diseases 2013, 13:109 Page 2 of 7
http://www.biomedcentral.com/1471-2334/13/109
imager by trained cytologists. The computer-based im-
aging technology employed for the primary cervical
screening for epithelial cell abnormalities used the
following classifications [22]: (1) negative for intrae-
pithelial lesion or malignancy (encompassing the pre-
vious category of “within normal limits”); (2) atypical
squamous or glandular cells of undetermined signifi-
cance (ASCUS, AGUS); (3) atypical squamous cells,
not excluding high-grade squamous intraepithelial le-
sion (ASC-H); (4) low-grade squamous intraepithelial
lesion (LSIL); (5) high-grade squamous intraepithelial
lesion (HSIL); and (6) squamous-cell or adenomatous
carcinoma (SC, AC). Many studies have confirmed that
ThinPrep liquid-based cytology has improved accuracy
and reading times, enhancing laboratory productivity
and clinical outcomes. This technology also allows
HPV testing of the same sample [23,24].
HPV genotyping was conducted using PCR, DNA
hybridization, and an HPV genotyping DNA chip
(Decipher Bioscience). An HPV typing kit (Guangdong
Hybribio Biotech) was used for quality control. An
HPV GenoArray Test Kit (HybrMax), based on “Flow-
through Hybridization” and certified for use by the
State Food and Drug Administration, was also used for
the rapid detection of 21 HPV genotypes. DNA was
extracted from samples and centrifuged (13,000 rpm
for 10 min). PCR assays were performed in reaction
tubes containing 5 μL of DNA and 20 μL of reaction
buffer containing specific biotin-tagged oligonucleo-
tide primers. Thermal cycling conditions involved
preheating at 50°C for 15 min, then an initial denatur-
ation step at 95°C for 10 min, followed by 40 cycles of
30 s at 94°C, 90 s at 42°C, and 30 s at 72°C, and then a
final extension step at 72°C for 5 min. Reverse
hybridization was performed using a line-probe assay
to enable the PCR products hybridized with specific
probes to fix to membranes. Chemical colorization
[0.1 M sodium citrate, tetramethylbenzidine (TMB)
substrate, 30% H2O2, 30 min] was then conducted to
visualize results.
Statistical analyses
Statistical analyses were performed using the SPSS version
17.0 for Windows (SPSS Inc., Chicago, IL, USA). Logistic
regression was used to estimate odds ratios (ORs) and
95% confidence intervals (CIs) to determine factors
associated with HPV infection. The influence of delivery
type and neonate gender on neonatal HPV infection was
analyzed using the χ2 or Fisher’s exact test. A P-value less
than 0.005 was considered statistically significant.
Results
The risk factors for HPV infection, and the cervical
prevalence of one or more HPV genotypes in the 3139
participants is outlined in Table 1. Overall prevalence of
HPV DNA was 13.4% (422/3139). The mean age of un-
infected women at delivery was 29.9 ± 3.5 years (mean ±
standard deviation; range, 20–44 years), while that of
HPV-positive women was 27.9 ± 3.5 years (range, 20–40 -
years). Prevalence of HPV was significantly higher in
women aged 24 years or younger (χ2 = 12.07, P = 0.001).
Prevalence of HPV in women experiencing their first
pregnancy was 13.8% (234/1692; χ2 = 0.67, P = 0.41). Par-
ity did not appear to be associated with HPV prevalence
(OR for ≥3 gestations vs. 1–2 gestations = 1.2, 95%
CI: 0.91–1.58). Most women in this study (72.4%) had
a level of education that went past secondary school.
A significant difference was seen in HPV prevalence
among women with different education levels (OR for
≤11 vs. ≥18 years = 4.4, 95% CI: 1.8–11.1; OR for 12–
17 years vs. ≥18 years = 32.0, 95% CI: 1.2–7.4; P <
0.01). Abnormal cervical cytological results were
found in 42 (1.3%) women, with an HPV prevalence
of 76.2% (32/42).
Figure 1 shows the HPV genotypes and frequencies of
detection in mothers and neonates. A high proportion of
the HPV-positive women (95.5%, 403/422) were infected
with high-risk HPV genotypes. The most frequently
detected HPV genotypes were HPV-16 (29.6%, 125/422),
-18 (14.7%, 62/422), and -58 (14.2%, 60/422). The HPV-
16 and -18 genotypes, which can be vaccinated against,
Table 1 Risk factors for prevalence of HPV DNA among
pregnant women







≤24 62/348 (17.8%) 1.2 0.85–1.67
25–29 243/2032 (12.%) 0.75 0.58–0.95
≥30 117/759 (15.4%) Reference -
Parity
1–2 348/2662 (13.1%) Reference -
≥3 73/477 (15.3%) 1.2 0.91–1.58
Education
(years)
≤11 150/865 (17.3%) 4.4 1.78–11.09
12–17 267/2163 (12.3%) 3.0 1.21–7.39
≥18 5/111 (4.5%) Reference -
Cytological
result
Normal 390/3097 (12.6%) Reference -
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accounted for 44.3% (187/422) of HPV infections. Of the
422 HPV-positive samples, 353 (83.6%) contained a sin-
gle virus genotype, while 69 (16.3%) were positive for
two or more HPV genotypes. HPV-16 DNA was present
in 46.4% (32/69) of samples that were identified as
containing multiple HPV genotypes.
In 23.6% (55/233) of neonates, the oral and/or genital
mucosa were positive for HPV DNA. No significant dif-
ference was seen between male and female infants (χ2 =
1.64, P = 0.268), or between the type of delivery (χ2 =
0.283, P = 0.71). The HPV-16 genotype accounted for
the majority (56.4%, 31/55) of infections in infants. In
233 mother-neonate pairs, the HPV DNA concordance
rate between mothers and newborns was 23.6% (55/
233). HPV type-specific concordance occurred in 26
cases, with HPV-16 the most frequently detected geno-
type (18/26), followed by HPV-11 (2/26) and -31 (2/26)
(Table 2).
Delivery type did not significantly affect the rate of
vertical transmission from HPV-positive mothers, where
58.4% (36/233) of the tested neonates were delivered va-
ginally and 41.6% (97/233) were delivered by cesarean
sections (χ2 = 0.119, P > 0.005). The HPV DNA concord-
ance rate between these 233 mother-neonate pairs was
23.6% (55/233). HPV type-specific concordance occurred
in 26 cases (11.2%) and HPV-16 was the most frequently
detected genotype (Table 3).
Discussion
In this study we examined the vertical transmission of
HPV DNA in a large patient population. Our findings
revealed that type-specific HPV discordance was high,
suggesting other infection routes besides the maternal-
neonate route. Although the prevalence of HPV in
mothers with abnormal cervical cytology (76.2%) was
much higher than that of mothers with normal cytology,
none of the 19 neonates from mothers with abnormal
cytology were HPV-positive. There was no significant in-
fluence of delivery type on the vertical transmission of
HPV, which is consistent with reports of congenital con-
dyloma after cesarean section without premature rup-
ture of membranes [25]. Delivery via cesarean section
did not eliminate the risk of vertical transmission,
suggesting that such transmission of HPV DNA may
occur before birth by the transplacental route. Several
studies have found HPV can be found in the amniotic
fluid, fetal membranes, and cord blood [26-28]. Disparity
of HPV genotypes in maternal and neonatal HPV DNA-
positive samples occurred in 52.7% of cases, indicating
transmission by fomites (i.e., contaminated instruments),
contact with the child after birth, or experimental con-
tamination of the samples might have occurred.
Figure 1 Prevalence of HPV-6, -11, -43, -16, -18, -33, -56, -58 (and multiple infections) among 422 HPV DNA-positive women and 55
HPV DNA-positive newborns.
Table 2 Neonatal HPV status among 233 infants with
HPV-positive mothers
HPV status Male (cases) Female (cases) Total (cases)
HPV+ 12 23 35
HPV- 91 107 198
Total 103 130 233
Table 3 Neonatal HPV status by delivery type
Cesarean section Vaginal delivery Total
HPV+ 16 19 35
HPV- 81 117 198
Total 97 136 233
Among the 233 infants with HPV-positive mothers, 103 (44.2%) were males
and 136 (58.4%) were born by vaginal delivery. No significant difference was
seen between male and female infants (χ2 = 1.64, P = 0.268), or between
different delivery types (χ2 = 0.283, P = 0.71).
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Ping et al. [1] previously reported the detection of
HPV-6, -11, -16, and -18 in cervical and vaginal
secretions, and in peripheral venous blood samples in
women at the latter stages of gestation. Following birth,
neonate pharyngeal secretions were also positive for
HPV-6, -11, -16, and -18. The prevalence of HPV DNA
in the cervical, vaginal exfoliated cells has been shown
to be low during the early stages of pregnancy (5/30
cases) and in the second trimester (12/42cases), with
prevalence increasing in the final trimester (23/31 cases).
In the third trimester, this prevalence was significantly
different compared with that during the first two
trimesters. Successive examinations on positive women
for HPV-6, -11, -16, and -18 in infants at time of birth,
48 ~ 72 h and 6 weeks after birth showed positive
HPVDNA in the nasopharyngeal secretion of 13, 6 cases
and 1 case with respect to the examining periods. The
positive cases were mainly infected by HPV- 16, 18.
Pregnant women in Jiangsu Province usually begin
routine obstetric care around the 24th week of gestation;
81.5% of the women in our study were at weeks 22–26
of gestation. Given this small interval of gestational age,
it was not possible to examine the influence of this vari-
able on HPV infection in pregnant women. It was previ-
ously found that HPV infection in pregnant women was
primarily associated with maternal age and education.
The influence of education level on HPV infection is
most likely explained by the early age of first sexual
intercourse and first pregnancy [28].
The microarray used in this study was developed by
Decipher Bioscience to detect 23 HPV genotypes. As a
diagnostic tool, the application of microarray technology
has the advantage of discriminating HPV genotypes and
detecting infection of multiple HPV subtypes [29]. In a
population-based cross-sectional screening study of
1137 women aged 15–59 years in Shenzhen, Li et al.
[30] confirmed the clinical value of this technology for
the detection of HPV in cervical cancer screening. Halfo
et al. [31] found a 93% concordance (k = 0.82) between
the HC-II assay and microarray technology, indicating
that microarrays are highly sensitive and specific in the
detection of HPV genotypes. The PCR conducted to de-
tect HPV DNA in pregnant women and showed that
viral DNA could be detected in exfoliated cervical and
vaginal cells. Additionally, this assay also detected DNA
for HPV-16, -11, -6, -35, -31, -58. In all cases except
one, the HPV DNA detected in the newborn was the
same genotype as that detected in the mother [32,33].
Immunological or hormonal changes may alter the
prevalence of HPV and its clearance during pregnancy
[34]. Some researchers have reported decreased clear-
ance of high-risk HPV types in the first two trimesters
of pregnancy [34,35], contributing to a high prevalence
of HPV during pregnancy. The prevalence of HPV DNA
among pregnant women that we observed (13.4%) was
similar to that reported by a multicenter epidemiological
survey for the general female population of China
(13.8%) [36]. Similarly, Zhang et al. [37] found no sig-
nificant difference between prevalence of HPV DNA and
the pregnancy status of 711 women in Beijing.
The prophylactic bivalent HPV 16/18 vaccine
manufactured by GlaxoSmithKline is currently in phase-
III clinical trials in Jiangsu Province. Few studies have
evaluated the safety of this vaccine for pregnant women
in China. Given that primary target population of the
HPV vaccine is women of a reproductive age, the risks
associated with its administration during pregnancy are
important factors affecting personal decisions and public
health policy. In a study of 3599 pregnancies, Wacholder
et al. [15] detected a small increase in the risk of miscar-
riage for pregnancies conceived within 3 months of
vaccination.
The present study found a high prevalence of HPV
among pregnant women in Nanjing, the urban center of
a highly developed province in China. This prevalence
did not differ significantly from that found among the
general female population of China. Although some ver-
tical transmission was documented, the high rate of dis-
cordance in the HPV genotypes of mothers and
neonates indicates the need for efforts to prevent hori-
zontal transmission. Subsequent investigations should
examine the role of viral load in vertical transmission.
This large-scale investigation evaluated the prevalence
of HPV infection in pregnant women and the rate of
vertical transmission. The most frequently detected HPV
genotypes in mothers and neonates were HPV-16 and -
18, consistent with the target genotypes of HPV
vaccines. Currently, no vaccine recommendations for
pregnant women have been provided and it is hoped
that the current study provides preliminary information
that can guide appropriate vaccination strategies for
mothers and newborns.
Conclusion
The most frequently detected HPV genotype in pregnant
women and newborns was HPV-16.
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